Literature DB >> 29198917

Early impact of universal varicella vaccination on childhood varicella and herpes zoster hospitalizations in Brazil.

Marcelo Comerlato Scotta1, Rolando Paternina-de la Ossa2, Magali Santos Lumertz3, Marcus Herbert Jones4, Rita Mattiello5, Leonardo Araújo Pinto6.   

Abstract

INTRODUCTION: The Brazilian childhood National Immunization Program (NIP) introduced live and attenuated varicella vaccination in a single dose, combined as tetraviral vaccine, at 15 months of age in the whole country, during September to December of 2013. The aim of this study was to report trends in incidence of childhood hospital admissions related to varicella and zoster in Brazil from 2003 to 2016, including the first three years after vaccine introduction.
METHODS: The number and incidence of hospital admission in patients aged less than 20 years in Brazilian public health system with an admission diagnosis of varicella and zoster from 2003 to 2016 were analyzed and pre (2003-2013) and post-vaccination periods (2014-2016) were compared. The data were obtained from DATASUS, a Brazilian government's open-access public health database system, and analyzed adjusting for secular trend and seasonality if a statistically significant change was found.
RESULTS: During the study period, 69,791 admissions due to varicella and herpes zoster occurred in the children younger than 20 years. After adjusting for seasonality, the incidence of hospitalizations decreased from 27.33 to 14.33 per 100000 per year, which corresponds to a reduction of 47.6% (95% confidence interval 18.19-77.04%, p < 0.001) in the vaccinated age group (1-4 years) in 2014-2016 compared to pre-vaccination period. The changes were not significant in the unvaccinated age groups.
CONCLUSION: The hospitalizations due to varicella and herpes zoster were decreased by half early after the introduction of a single dose of tetraviral vaccine in NIP in the vaccinated children. Further studies may assess duration and intensity of this effect, as well as the indirect effect in the unvaccinated age groups.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chickenpox; Child; Herpes zoster; Hospitalizations; Shingles; Varicella

Mesh:

Substances:

Year:  2017        PMID: 29198917     DOI: 10.1016/j.vaccine.2017.11.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  NUMBER OF CASES OF VARICELLA AND HOSPITALIZATION IN A PEDIATRIC REFERENCE HOSPITAL IN BRAZIL AFTER INTRODUCING THE VACCINE.

Authors:  Henrique Botelho de Abreu E Silva; Isabella Cristina Tristão Pinto; José Geraldo Leite Ribeiro; Leonardo Santos Resende; Ludymila Keren de Carvalho; Marcelle Marie Martins Maia; Roberto Ferreira de Almeida Araújo; Lilian Martins Oliveira Diniz
Journal:  Rev Paul Pediatr       Date:  2020-07-03

2.  Herpes Zoster Onset 9 Years After First Varicella Zoster Vaccination in an 11-year-old Child - A Case Report.

Authors:  Kerasia-Maria Plachouri; Despoina Gkentzi; Anastasia Varvarigou; Sophia Georgiou; Gabriel Dimitriou
Journal:  Curr Pediatr Rev       Date:  2019

3.  Impact of maternal dTpa vaccination on the incidence of pertussis in young infants.

Authors:  Frederico Friedrich; Maria Clara Valadão; Marcos Brum; Talitha Comaru; Paulo Márcio Pitrez; Marcus Herbert Jones; Leonardo A Pinto; Marcelo C Scotta
Journal:  PLoS One       Date:  2020-01-28       Impact factor: 3.240

4.  Trends in Varicella Burden of Disease Following Introduction of Routine Childhood Varicella Vaccination in Argentina: A 12-Year Time Series Analysis.

Authors:  Norberto Giglio; Pieralessandro Lasalvia; Manjiri Pawaskar; Cintia I Parellada; Yaneth Gil Rojas; Paula Micone; Virginia V Babic; Silvina E Neyro
Journal:  Vaccines (Basel)       Date:  2022-07-20

5.  Impact of the tetra viral vaccine introduction on varicella morbidity and mortality in the Brazilian macro regions.

Authors:  Marcella Z Ribeiro; Emil Kupek; Paulo V Z Ribeiro; Carlos Eduardo Andrade Pinheiro
Journal:  J Pediatr (Rio J)       Date:  2019-12-18       Impact factor: 2.990

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.